NCT00141765

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.

Detailed description

This is a phase II trial designed to provide a transplant option for patients with rare poor-prognosis cancers. The protocol is only open to patients with metastatic or relapsed cancers for whom the probability of remaining free of progressive disease for one year after being brought into remission is \< 25%. Patients eligible for this study have been diagnosed with a form of cancer that leads to death more than 75% of the time when treated with standard therapy doses of chemotherapy and/ or radiation therapy. Under this treatment intensification protocol the expectation is that the one year progression-free survival for this group of patients will rise to 40%. Patients eligible for this protocol will be followed for one year post-transplant. Patients alive and free of progressive disease at the end of this period will be considered successes.

Conditions

• Wilms Tumor
• Fibrosarcoma
• Carcinoma, Round Cell
• Nasopharyngeal Cancer
• Brain Tumor, Recurrent

Interventions

Type	Name	Description
PROCEDURE	Myeloablative Chemotherapy	High dose chemotherapy (carboplatin and thiotepa) transplant rescue
PROCEDURE	Stem Cell Rescue	autologous stem cell transplantation

Timeline

• Start date: 1997-01-01
• Primary completion: 2008-12-01
• Completion: 2010-02-01
• First posted: 2005-09-01
• Last updated: 2014-06-20
• Results posted: 2014-06-20

Locations

1 site across 1 country: United States